News | October 27, 2022
Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Subscribe To Our Newsletter & Stay Updated
